MedTrace Logo

A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

NCT03069378 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2025-10-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine how well the combination of therapy of talimogene laherparepvec (T-VEC) and pembrolizumab works in the treatment of patients with sarcoma.

Conditions

  • Sarcoma
  • Epithelioid Sarcoma
  • Cutaneous Angiosarcoma

Interventions

DRUG

Talimogene Laherparepvec (T-VEC)

Talimogene laherparepvec treatment will be given at Day 1 Week 1, and every 3 weeks thereafter .

DRUG

Pembrolizumab

Pembrolizumab will be given at Day 1 week 1 and every 3 weeks thereafter.

Sponsors & Collaborators

Principal Investigators

  • Ciara Kelly, MBBCh BAO · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-03
Primary Completion
2025-07-22
Completion
2026-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03069378 on ClinicalTrials.gov